donepezil has been researched along with Acute Onset Vascular Dementia in 69 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study investigates the effect of ozagrel, a selective thromboxane A2 (TXA2) inhibitor, in rat model of hyperhomocysteinemia (HHcy)-induced vascular cognitive impairment and dementia (VCID)." | 8.02 | Ameliorative effect of ozagrel, a thromboxane A2 synthase inhibitor, in hyperhomocysteinemia-induced experimental vascular cognitive impairment and dementia. ( Bhatia, P; Singh, N, 2021) |
| "This study was designed to investigate the effects of fisetin (FST) on hyperhomocysteinemia (HHcy)-induced experimental endothelial dysfunction (ED) and vascular dementia (VaD) in rats." | 7.85 | Effects of fisetin on hyperhomocysteinemia-induced experimental endothelial dysfunction and vascular dementia. ( Arun Reddy, R; Dinesh Kumar, B; Diwan, PV; Hemanth Kumar, B; Mahesh Kumar, J, 2017) |
| "Sixteen patients with Alzheimer's disease (AD) and 15 patients with vascular dementia (VaD) associated with subcortical white matter lesions or subcortical cardiovascular accidents (CVAs) were treated with donepezil for 16 weeks." | 7.73 | Treating dementia patients with vascular lesions with donepezil: a preliminary analysis. ( Ledakis, GE; Libon, DJ; Thomas, DA, 2005) |
| "0 years) with probable or possible VaD, according to National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche en l'Enseignement en Neurosciences criteria, were randomized to receive donepezil 5 mg/day (n = 208), donepezil 10 mg/day (after 5 mg/day for the first 28 days) (n = 215), or placebo (n = 193) for 24 weeks." | 5.10 | Donepezil in vascular dementia: a randomized, placebo-controlled study. ( Doody, R; Helme, R; Kertesz, A; Mintzer, J; Pratt, RD; Taubman, K; Wilkinson, D, 2003) |
| "Some randomized studies, mostly of short duration, have indicated that cholinesterase inhibitors (donepezil, rivastigmine and galantamine) may have a beneficial effect in Alzheimer's disease, vascular dementia and in dementia caused by Lewy body disease." | 4.84 | [Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?]. ( Landmark, K; Reikvam, A, 2008) |
| "The present study investigates the effect of ozagrel, a selective thromboxane A2 (TXA2) inhibitor, in rat model of hyperhomocysteinemia (HHcy)-induced vascular cognitive impairment and dementia (VCID)." | 4.02 | Ameliorative effect of ozagrel, a thromboxane A2 synthase inhibitor, in hyperhomocysteinemia-induced experimental vascular cognitive impairment and dementia. ( Bhatia, P; Singh, N, 2021) |
| "This study was designed to investigate the effects of fisetin (FST) on hyperhomocysteinemia (HHcy)-induced experimental endothelial dysfunction (ED) and vascular dementia (VaD) in rats." | 3.85 | Effects of fisetin on hyperhomocysteinemia-induced experimental endothelial dysfunction and vascular dementia. ( Arun Reddy, R; Dinesh Kumar, B; Diwan, PV; Hemanth Kumar, B; Mahesh Kumar, J, 2017) |
| "All four dementia drugs available on the Swedish market (three cholinesterase inhibitors [donepezil, rivastigmine and galantamine] and memantine) were prescribed at the two dementia clinics." | 3.79 | Is drug treatment for dementia followed up in primary care? A Swedish study of dementia clinics and referring primary care centres. ( Johnell, K; Sonde, L, 2013) |
| "Sixteen patients with Alzheimer's disease (AD) and 15 patients with vascular dementia (VaD) associated with subcortical white matter lesions or subcortical cardiovascular accidents (CVAs) were treated with donepezil for 16 weeks." | 3.73 | Treating dementia patients with vascular lesions with donepezil: a preliminary analysis. ( Ledakis, GE; Libon, DJ; Thomas, DA, 2005) |
| "Donepezil hydrochloride combined with nimodipine had good efficacy in the treatment of patients with vascular dementia, mainly in terms of improving the Simple MMSE scores, the ability to use daily living scale (ADL) scores and the CDR, and the best results were obtained after 12 weeks of intervention." | 2.82 | A systematic review of the efficacy of donepezil hydrochloride combined with nimodipine on treating vascular dementia. ( Huang, KL; Liu, J; Ran, SM; Tan, AH; Wang, GY; Wang, MY; Yang, Q, 2022) |
| "It is clinically used for the treatment of vascular dementia (VaD)." | 2.82 | Gunao-Yizhi decoction combined with donepezil for vascular dementia: A systematic review and meta-analysis. ( Bi, S; Guan, X; Hou, H; Hu, Y; Li, M; Liu, C; Wang, K; Zhang, L, 2022) |
| "The main outcome measure was the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-cog)." | 2.75 | The long-term efficacy and tolerability of donepezil in patients with vascular dementia. ( Boundy, K; Hecker, J; Kumar, D; Posner, H; Róman, G; Salloway, S; Schindler, R; Wilkinson, D, 2010) |
| "Donepezil was relatively well tolerated; adverse events were consistent with current labeling." | 2.75 | Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. ( Black, SE; Decarli, C; Kumar, D; Moline, M; Posner, H; Román, GC; Royall, DR; Salloway, S; Schindler, R; Weiner, MW, 2010) |
| "After Alzheimer's disease (AD), vascular dementia (VaD) is the most common cause of dementia among the elderly." | 2.72 | P300 auditory event-related potentials and neuropsychological study during donepezil treatment in vascular dementia. ( Carboni, T; Curatola, L; Gobbato, R; Paci, C; Sanguigni, S; Santone, A, 2006) |
| "Donepezil-treated patients showed significant benefits in activities of daily living over placebo on the Alzheimer's Disease Functional Assessment and Change Scale (mean change from baseline score effect size at week 24: donepezil 5 mg/d, -1." | 2.71 | Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. ( Black, S; Burns, A; Geldmacher, DS; Hecker, J; Kumar, D; Perdomo, C; Pratt, R; Román, GC; Salloway, S, 2003) |
| "Donepezil was well tolerated, with low withdrawal rates due to adverse events." | 2.71 | Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. ( Black, SE; Doody, RS; Román, GC; Salloway, SP; Schindler, RJ; Wilkinson, DG, 2005) |
| "Studies in patients with vascular dementia, who had not taken acetylcholinesterase inhibitors or memantine for at least 6 weeks, were included." | 2.53 | Efficacy of Cholinesterase Inhibitors in Vascular Dementia: An Updated Meta-Analysis. ( Chen, YD; Hu, WL; Wang, Y; Yuan, JL; Zhang, J, 2016) |
| " Compared with placebo, more dropouts and adverse events (anorexia, nausea, vomiting, diarrhoea, and insomnia) occurred with the cholinesterase inhibitors, but not with memantine." | 2.44 | Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. ( Kavirajan, H; Schneider, LS, 2007) |
| "Alzheimer's disease (AD) and vascular dementia (VaD) are both associated with deficits in cholinergic neurotransmission that are amenable to therapeutic intervention." | 2.43 | Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials. ( Bayer, AJ; Passmore, AP; Steinhagen-Thiessen, E, 2005) |
| "Patients with vascular dementia (VaD) and Alzheimer's disease with cerebrovascular disease (AD + CVD) have dementia associated with underlying CVD." | 2.43 | Dementia with cerebrovascular disease: the benefits of early treatment. ( Schindler, RJ, 2005) |
| "Stroke is the leading cause of VaD, although it may also develop secondary to a variety of other cerebrovascular or cardiovascular conditions." | 2.43 | Use of antidementia agents in vascular dementia: beyond Alzheimer disease. ( Farlow, MR, 2006) |
| "Donepezil was generally well tolerated in patients with VaD." | 2.42 | Donepezil: in vascular dementia. ( Goldsmith, DR; Scott, LJ, 2003) |
| "Donepezil does not cause liver toxicity or significant drug interactions and is relatively well-tolerated." | 2.42 | Donepezil: a clinical review of current and emerging indications. ( Rogers, SJ; Román, GC, 2004) |
| " Activities of daily living and social behaviour: On the Instrumental Activity of Daily Living (IADL) scale, there was no statistically significant difference between the groups taking donepezil 5mg per day donepezil and placebo, but the group taking 10 mg of donepezil a day showed benefit compared with placebo There were statistically significant benefit for donepezil at either dosage compared with placebo on the Alzheimer's Disease Functional Assessment and Change Scale (ADFACS)." | 2.42 | Donepezil for vascular cognitive impairment. ( Birks, J; Malouf, R, 2004) |
| "By contrast, vascular dementia subtypes (VaD) are heterogeneous clinical syndromes, and therapeutic approaches have been directed toward control of vascular risk factors." | 2.41 | Donepezil treatment of vascular dementia. ( Chowdhury, MH; Li, YS; Meyer, JS; Quach, M; Xu, G, 2002) |
| "Donepezil is an acetylcholinesterase inhibitor that is currently used in patients with mild to moderate AD, and has recently been shown to improve cognitive performance in patients with VaD." | 1.56 | Donepezil down-regulates propionylation, 2-hydroxyisobutyrylation, butyrylation, succinylation, and crotonylation in the brain of bilateral common carotid artery occlusion-induced vascular dementia rats. ( Chen, C; Ding, Z; Gao, WC; Li, N; Lu, J; Ma, X; Qiao, G; Wang, H; Weng, Z; Wu, C; Xiao, C; Yang, W; Zhang, C; Zheng, CB; Zhu, M, 2020) |
| "Dyslipidemia was assessed by estimation of serum lipid levels including total cholesterol, triglyceride, HDL, and LDL levels." | 1.42 | Beneficial Effect of Protein Tyrosine Phosphatase Inhibitor and Phytoestrogen in Dyslipidemia-Induced Vascular Dementia in Ovariectomized Rats. ( Sharma, S; Verma, A, 2015) |
| "Donepezil hydrochloride is an acetylcholinesterase inhibitor (AChEI) currently used for the symptomatic treatment of Alzheimer's disease (AD)." | 1.40 | Effects of donepezil, an acetylcholinesterase inhibitor, on neurogenesis in a rat model of vascular dementia. ( Cho, KS; Choi, BR; Han, JS; Han, SH; Kim, HY; Kim, JN; Kim, MK; Kim, SY; Kwon, KJ; Lee, EJ; Shin, CY, 2014) |
| " Demographic variables, quantity and rate of prescriptions, dosage forms and strengths were analyzed." | 1.39 | [Drugs used for cognitive impairment. Analysis of 1.5 million prescriptions in Argentina]. ( Arizaga, RL; Demey, I; Rojas, G, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.45) | 18.2507 |
| 2000's | 41 (59.42) | 29.6817 |
| 2010's | 18 (26.09) | 24.3611 |
| 2020's | 9 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, Y | 2 |
| Zhou, Q | 3 |
| Zhang, T | 1 |
| Li, Z | 3 |
| Chen, YP | 1 |
| Zhang, P | 1 |
| Yu, YF | 1 |
| Geng, H | 1 |
| Tian, YJ | 1 |
| Zhang, C | 2 |
| Wang, Y | 2 |
| Chen, JW | 1 |
| Chen, Y | 1 |
| Luo, HB | 3 |
| Liang, J | 1 |
| Huang, YY | 1 |
| Gao, Y | 1 |
| Wu, D | 1 |
| Yu, S | 1 |
| Guo, L | 2 |
| Chen, Z | 1 |
| Huang, L | 1 |
| Liang, SH | 1 |
| He, X | 1 |
| Wu, R | 1 |
| Huang, Y | 2 |
| Wu, XN | 1 |
| Zheng, D | 1 |
| Yang, GX | 1 |
| Sun, JM | 1 |
| Zheng, LL | 1 |
| Zhang, L | 2 |
| Li, J | 1 |
| Gan, HX | 1 |
| Huang, J | 1 |
| Diao, XX | 1 |
| Tang, Y | 1 |
| Wang, R | 1 |
| Ma, L | 1 |
| Yang, Q | 1 |
| Liu, J | 1 |
| Huang, KL | 1 |
| Wang, GY | 1 |
| Wang, MY | 1 |
| Tan, AH | 1 |
| Ran, SM | 1 |
| Hu, Y | 1 |
| Guan, X | 1 |
| Hou, H | 1 |
| Bi, S | 1 |
| Liu, C | 1 |
| Li, M | 1 |
| Wang, K | 1 |
| Sun, Y | 1 |
| Wei, YJ | 1 |
| Xing, Y | 1 |
| Jian, WX | 1 |
| Zhang, Z | 1 |
| Zhan, JH | 1 |
| Chu, SF | 1 |
| Peng, Y | 1 |
| Zhao, M | 1 |
| Wang, Q | 1 |
| Chen, NH | 1 |
| Wang, H | 1 |
| Lu, J | 1 |
| Gao, WC | 1 |
| Ma, X | 1 |
| Li, N | 1 |
| Ding, Z | 1 |
| Wu, C | 1 |
| Zhu, M | 1 |
| Qiao, G | 1 |
| Xiao, C | 1 |
| Chen, C | 1 |
| Weng, Z | 1 |
| Yang, W | 1 |
| Zheng, CB | 1 |
| Bhatia, P | 1 |
| Singh, N | 1 |
| Battle, CE | 1 |
| Abdul-Rahim, AH | 1 |
| Shenkin, SD | 1 |
| Hewitt, J | 1 |
| Quinn, TJ | 1 |
| Akechi, T | 1 |
| Suzuki, M | 1 |
| Hashimoto, N | 1 |
| Yamada, T | 1 |
| Yamada, A | 1 |
| Nakaaki, S | 1 |
| Sonde, L | 1 |
| Johnell, K | 1 |
| Rojas, G | 1 |
| Demey, I | 1 |
| Arizaga, RL | 1 |
| Damulin, IV | 1 |
| Sakr, HF | 1 |
| Khalil, KI | 1 |
| Hussein, AM | 1 |
| Zaki, MS | 1 |
| Eid, RA | 1 |
| Alkhateeb, M | 1 |
| Kwon, KJ | 1 |
| Kim, MK | 1 |
| Lee, EJ | 1 |
| Kim, JN | 1 |
| Choi, BR | 1 |
| Kim, SY | 1 |
| Cho, KS | 1 |
| Han, JS | 1 |
| Kim, HY | 1 |
| Shin, CY | 1 |
| Han, SH | 1 |
| Jian, WJ | 1 |
| Shi, J | 1 |
| Tian, JZ | 1 |
| Ni, JN | 1 |
| Bachyns'ka, NIu | 1 |
| Rozheliuk, IF | 1 |
| Kholyn, VO | 1 |
| Pishel', IM | 1 |
| Leonov, IuI | 1 |
| Verma, A | 1 |
| Sharma, S | 1 |
| Chen, YD | 1 |
| Zhang, J | 1 |
| Yuan, JL | 1 |
| Hu, WL | 1 |
| Hemanth Kumar, B | 1 |
| Arun Reddy, R | 1 |
| Mahesh Kumar, J | 1 |
| Dinesh Kumar, B | 1 |
| Diwan, PV | 1 |
| Assal, F | 1 |
| Bogousslavsky, J | 1 |
| Wang, J | 2 |
| Zhang, HY | 1 |
| Tang, XC | 1 |
| Wilkinson, D | 2 |
| Róman, G | 3 |
| Salloway, S | 3 |
| Hecker, J | 2 |
| Boundy, K | 1 |
| Kumar, D | 3 |
| Posner, H | 2 |
| Schindler, R | 2 |
| Román, GC | 5 |
| Black, SE | 3 |
| Royall, DR | 1 |
| Decarli, C | 1 |
| Weiner, MW | 1 |
| Moline, M | 1 |
| Sato, K | 1 |
| Urbano, R | 1 |
| Yu, C | 1 |
| Yamasaki, F | 1 |
| Sato, T | 1 |
| Jordan, J | 1 |
| Robertson, D | 1 |
| Diedrich, A | 1 |
| Collins, C | 1 |
| Copeland, B | 1 |
| Croucher, M | 1 |
| Xiao, Y | 1 |
| Jiang, S | 1 |
| Luo, H | 1 |
| Pratt, RD | 4 |
| Meyer, JS | 2 |
| Chowdhury, MH | 2 |
| Xu, G | 1 |
| Li, YS | 1 |
| Quach, M | 2 |
| Perdomo, CA | 1 |
| Bowler, JV | 1 |
| Rabadi, MH | 1 |
| Blass, J | 1 |
| Doody, R | 1 |
| Helme, R | 1 |
| Taubman, K | 1 |
| Mintzer, J | 1 |
| Kertesz, A | 1 |
| Black, S | 1 |
| Geldmacher, DS | 2 |
| Burns, A | 1 |
| Perdomo, C | 1 |
| Pratt, R | 1 |
| Bonelli, RM | 1 |
| Fuchsberger, T | 1 |
| Möller, HJ | 1 |
| Hampel, H | 1 |
| Baezner, H | 1 |
| Daffertshofer, M | 1 |
| Goldsmith, DR | 1 |
| Scott, LJ | 1 |
| Rogers, SJ | 1 |
| Malouf, R | 1 |
| Birks, J | 1 |
| Johnson, KD | 1 |
| Erkinjuntti, T | 2 |
| Gauthier, S | 2 |
| Feldman, H | 1 |
| Rockwood, K | 1 |
| Eto, F | 1 |
| Blasko, I | 1 |
| Bodner, T | 1 |
| Knaus, G | 1 |
| Walch, T | 1 |
| Monsch, A | 1 |
| Hinterhuber, H | 1 |
| Marksteiner, J | 1 |
| Ebell, MH | 1 |
| Passmore, AP | 1 |
| Bayer, AJ | 1 |
| Steinhagen-Thiessen, E | 1 |
| Thomas, DA | 1 |
| Libon, DJ | 1 |
| Ledakis, GE | 1 |
| Schindler, RJ | 2 |
| Wilkinson, DG | 1 |
| Doody, RS | 1 |
| Salloway, SP | 1 |
| Paci, C | 1 |
| Gobbato, R | 1 |
| Carboni, T | 1 |
| Sanguigni, S | 1 |
| Santone, A | 1 |
| Curatola, L | 1 |
| Martínez-Vila, E | 1 |
| Murie-Fernández, M | 1 |
| Gállego Pérez-Larraya, J | 1 |
| Irimia, P | 1 |
| Formiga, F | 1 |
| Fort, I | 1 |
| Pérez-Castejón, JM | 1 |
| Ruiz, D | 1 |
| Duaso, E | 1 |
| Riu, S | 1 |
| Johannsen, P | 1 |
| Farlow, MR | 1 |
| Kavirajan, H | 1 |
| Schneider, LS | 1 |
| Yan, YX | 1 |
| Liang, LZ | 1 |
| Zhou, ZL | 1 |
| Nyenhuis, DL | 1 |
| Gorelick, PB | 1 |
| Landmark, K | 1 |
| Reikvam, A | 1 |
| Mendez, MF | 1 |
| Younesi, FL | 1 |
| Perryman, KM | 1 |
| Li, Y | 1 |
| Haque, MA | 1 |
| Hinh, P | 1 |
| González Moneo, MJ | 1 |
| Garrido Barral, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 6 Months, Prospective, Open-label, Observational, Non-interventional Clinical Trial to Examine the Efficacy and Safety of Donepezil (Dementis®) Administration in Patients With Dementia.[NCT01772095] | 389 participants (Actual) | Observational | 2013-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
25 reviews available for donepezil and Acute Onset Vascular Dementia
| Article | Year |
|---|---|
A systematic review of the efficacy of donepezil hydrochloride combined with nimodipine on treating vascular dementia.
Topics: Alzheimer Disease; Dementia, Vascular; Donepezil; Humans; Mental Status and Dementia Tests; Nimodipi | 2022 |
Gunao-Yizhi decoction combined with donepezil for vascular dementia: A systematic review and meta-analysis.
Topics: Dementia, Vascular; Donepezil; Drugs, Chinese Herbal; Humans; Malondialdehyde; Superoxide Dismutase | 2022 |
Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
Topics: Activities of Daily Living; Bias; Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Donepezi | 2021 |
[Donepezil in Alzheimer's disease and vascular dementia].
Topics: Alzheimer Disease; Dementia, Vascular; Donepezil; Humans; Indans; Nootropic Agents; Piperidines; Tre | 2013 |
[Treatment of vascular dementia by Chinese herbal medicine: a systematic review of randomized controlled trials of clinical studies].
Topics: Complementary Therapies; Dementia, Vascular; Donepezil; Drugs, Chinese Herbal; Humans; Indans; Piper | 2015 |
Efficacy of Cholinesterase Inhibitors in Vascular Dementia: An Updated Meta-Analysis.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Dementia, Vascular; Donepezil; Female; Galantami | 2016 |
Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.
Topics: Acetylcholine; Alkaloids; Animals; Anti-Inflammatory Agents; Cholinergic Agents; Cholinesterase Inhi | 2009 |
Hyperbaric oxygen therapy for vascular dementia.
Topics: Cognition; Combined Modality Therapy; Dementia, Vascular; Donepezil; Humans; Hyperbaric Oxygenation; | 2012 |
Donepezil treatment of vascular dementia.
Topics: Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Donepezil; Humans; Indans; Nootropic Agent | 2002 |
[Current therapy of patients with dementia].
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Controlled Cli | 2003 |
[Subcortical vascular encephalopathy].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amantadine; Brain; Carbamates; Clinical Trials as Topic; | 2003 |
Donepezil: in vascular dementia.
Topics: Administration, Oral; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia, Vascular; Donep | 2003 |
Donepezil: a clinical review of current and emerging indications.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2004 |
Donepezil for vascular cognitive impairment.
Topics: Activities of Daily Living; Cognition Disorders; Dementia, Vascular; Donepezil; Humans; Indans; Noot | 2004 |
[Treatment of vascular dementia].
Topics: Activities of Daily Living; Anticoagulants; Cholinesterase Inhibitors; Dementia, Vascular; Donepezil | 2004 |
Treatment of vascular dementia--evidence from clinical trials with cholinesterase inhibitors.
Topics: Aged; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia, Vascular; Donepezil; Galantamin | 2004 |
Donepezil in the treatment of vascular dementia.
Topics: Cholinesterase Inhibitors; Dementia, Vascular; Donepezil; Dose-Response Relationship, Drug; Humans; | 2004 |
Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials.
Topics: Aged; Alzheimer Disease; Cognition; Dementia, Vascular; Donepezil; Female; Humans; Indans; Male; Mul | 2005 |
Dementia with cerebrovascular disease: the benefits of early treatment.
Topics: Cerebrovascular Disorders; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia, Vascular; | 2005 |
[Medical treatment of Alzheimer's disease].
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; | 2006 |
Use of antidementia agents in vascular dementia: beyond Alzheimer disease.
Topics: Cholinesterase Inhibitors; Dementia, Vascular; Diagnosis, Differential; Donepezil; Dopamine Agents; | 2006 |
Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
Topics: Cholinesterase Inhibitors; Databases, Bibliographic; Dementia, Vascular; Donepezil; Dose-Response Re | 2007 |
Diagnosis and management of vascular cognitive impairment.
Topics: Central Nervous System Agents; Clinical Trials as Topic; Cognition Disorders; Dementia, Vascular; Do | 2007 |
[Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Dementia, Vascular; Donepezil; Evidence-Base | 2008 |
[Latest therapies for treating dementia].
Topics: Adult; Aged; Alzheimer Disease; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepress | 2002 |
10 trials available for donepezil and Acute Onset Vascular Dementia
| Article | Year |
|---|---|
The long-term efficacy and tolerability of donepezil in patients with vascular dementia.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Donepezil; Double | 2010 |
Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size.
Topics: Adult; Aged; Aged, 80 and over; Cognition; Dementia, Vascular; Donepezil; Double-Blind Method; Femal | 2010 |
Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia.
Topics: Aged; Brain; Cerebrovascular Circulation; Cognition; Cohort Studies; Dementia, Vascular; Disease Pro | 2002 |
Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Donepezil; Female | 2002 |
Donepezil in vascular dementia: a randomized, placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Dementia, Vascular; Donepezil; Double-Bli | 2003 |
Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Cardiovascular System; Cholinesterase Inhibitor | 2003 |
Patient populations in clinical studies of donepezil in vascular dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Dementia, Vascular; Donepezil; Double-Blind Metho | 2003 |
Donepezil in vascular dementia: combined analysis of two large-scale clinical trials.
Topics: Activities of Daily Living; Aged; Cholinesterase Inhibitors; Clinical Protocols; Dementia, Vascular; | 2005 |
P300 auditory event-related potentials and neuropsychological study during donepezil treatment in vascular dementia.
Topics: Acoustic Stimulation; Aged; Dementia, Vascular; Donepezil; Electroencephalography; Event-Related Pot | 2006 |
[Clinical study of combined treatment with compound Reinhartdt and Sea Cumber Capsule and donepezil for vascular dementia].
Topics: Aged; Aged, 80 and over; Capsules; Dementia, Vascular; Donepezil; Drug Therapy, Combination; Drugs, | 2007 |
34 other studies available for donepezil and Acute Onset Vascular Dementia
| Article | Year |
|---|---|
Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Animals; Binding Sites; Catalytic Domain; | 2019 |
Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.
Topics: Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; De | 2020 |
Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenine; Administration, Oral; Animals; Behavior, Animal; Bindi | 2020 |
Twin drug design, synthesis and evaluation of diosgenin derivatives as multitargeted agents for the treatment of vascular dementia.
Topics: Acetylcholinesterase; Animals; Cell Survival; Central Nervous System Agents; Cholinesterase Inhibito | 2021 |
Vascular cognitive impairment associated with NOTCH3 Exon 33 mutation: A case report.
Topics: Cognitive Dysfunction; Dementia, Vascular; Donepezil; Humans; Male; Memantine; Middle Aged; Mutation | 2019 |
Donepezil attenuates vascular dementia in rats through increasing BDNF induced by reducing HDAC6 nuclear translocation.
Topics: Administration, Oral; Animals; Brain-Derived Neurotrophic Factor; Dementia, Vascular; Donepezil; His | 2020 |
Donepezil down-regulates propionylation, 2-hydroxyisobutyrylation, butyrylation, succinylation, and crotonylation in the brain of bilateral common carotid artery occlusion-induced vascular dementia rats.
Topics: Animals; Brain; Carotid Artery, Common; Cognition; Dementia, Vascular; Disease Models, Animal; Donep | 2020 |
Ameliorative effect of ozagrel, a thromboxane A2 synthase inhibitor, in hyperhomocysteinemia-induced experimental vascular cognitive impairment and dementia.
Topics: Animals; Dementia, Vascular; Donepezil; Endothelium, Vascular; Enzyme Inhibitors; Female; Hyperhomoc | 2021 |
Different pharmacological responses in late-life depression with subsequent dementia: a case supporting the reserve threshold theory.
Topics: Aged; Antidepressive Agents; Brain; Cholinesterase Inhibitors; Cognitive Reserve; Dementia, Vascular | 2017 |
Is drug treatment for dementia followed up in primary care? A Swedish study of dementia clinics and referring primary care centres.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Dementia, Vascular; Donepezil; Female; Galanta | 2013 |
[Drugs used for cognitive impairment. Analysis of 1.5 million prescriptions in Argentina].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Argentina; Child; Child, Preschool; Cholinesterase Inhib | 2013 |
Effect of dehydroepiandrosterone (DHEA) on memory and brain derived neurotrophic factor (BDNF) in a rat model of vascular dementia.
Topics: Acetylcholine; Animals; Brain-Derived Neurotrophic Factor; Carotid Artery, Common; Dehydroepiandrost | 2014 |
Effects of donepezil, an acetylcholinesterase inhibitor, on neurogenesis in a rat model of vascular dementia.
Topics: Animals; Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Dentate Gyrus; Disease Models, An | 2014 |
[ApoE gene polymorphism as a predictor of therapeutic response to treatment acetylcholinesterase inhibitor for elderly patients with Alzheimer's and vascular dementia types].
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; Dementia, Vascular; Donepezil | 2014 |
Beneficial Effect of Protein Tyrosine Phosphatase Inhibitor and Phytoestrogen in Dyslipidemia-Induced Vascular Dementia in Ovariectomized Rats.
Topics: Acetylcholinesterase; Animals; Avoidance Learning; Brain; Dementia, Vascular; Donepezil; Dyslipidemi | 2015 |
Effects of fisetin on hyperhomocysteinemia-induced experimental endothelial dysfunction and vascular dementia.
Topics: Acetylcholinesterase; Animals; Aorta; Brain; Catalase; Cholesterol; Dementia, Vascular; Donepezil; D | 2017 |
Clinical and therapeutic aspects of vascular dementia.
Topics: Brain; Dementia, Vascular; Diagnostic Imaging; Donepezil; Humans; Indans; Nootropic Agents; Piperidi | 2008 |
The effect of donepezil treatment on cardiovascular mortality.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cardiovascular Diseases; Cholinesterase Inhibitors; Coho | 2010 |
Bipolar affective disorder, type II, apparently precipitated by donepezil.
Topics: Aged; Bipolar Disorder; Cholinesterase Inhibitors; Dementia, Vascular; Donepezil; Female; Humans; In | 2011 |
Acetylcholinesterase inhibitors for vascular dementia and Alzheimer's disease combined with cerebrovascular disease.
Topics: Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition Disorders; Dement | 2003 |
Clinical trials in stroke in 2002.
Topics: Anticholesteremic Agents; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia, Vascular; D | 2003 |
Editorial comment--How to treat vascular dementia?
Topics: Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia, Vascular; Donepezil; Gala | 2003 |
Donepezil in vascular dementia: a viewpoint by David S. Geldmacher.
Topics: Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia, Vascular; Donepezil; Dose-Response Re | 2003 |
Donepezil in vascular dementia: a viewpoint by Gustavo C. Román.
Topics: Cholinesterase Inhibitors; Dementia, Vascular; Donepezil; Dose-Response Relationship, Drug; Humans; | 2003 |
Donepezil in vascular dementia: a viewpoint by Sandra E. Black.
Topics: Administration, Oral; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia, Vascular; Donep | 2003 |
Donepezil minimally effective for patients with vascular dementia.
Topics: Aged; Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Donepezil; Double-Blind Method; Huma | 2004 |
Emerging therapies for vascular dementia and vascular cognitive impairment.
Topics: Carbamates; Cardiovascular Diseases; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition | 2004 |
Efficacy of donepezil treatment in Alzheimer patients with and without subcortical vascular lesions.
Topics: Aged; Alzheimer Disease; Case-Control Studies; Comorbidity; Dementia, Vascular; Donepezil; Female; H | 2004 |
Treating dementia patients with vascular lesions with donepezil: a preliminary analysis.
Topics: Aged; Alzheimer Disease; Blood Vessels; Brain; Dementia; Dementia, Vascular; Donepezil; Female; Huma | 2005 |
Neuroprotection in vascular dementia.
Topics: Animals; Cholinesterase Inhibitors; Dementia, Vascular; Donepezil; Excitatory Amino Acid Antagonists | 2006 |
Alzheimer's drug proves risky in patients with vascular dementia.
Topics: Dementia, Vascular; Donepezil; Humans; Indans; Nootropic Agents; Piperidines | 2006 |
[Risperidone and cerebrovascular adverse effects in elderly patients with dementia].
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cerebrovascular Disorders; Cholinesterase Inhibitors; | 2006 |
Use of donepezil for vascular dementia: preliminary clinical experience.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Dementia, Vascular; Donepezil; Female; Humans; I | 1999 |
Feasibility of vascular dementia treatment with cholinesterase inhibitors.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Dementia, Vascular; Donepezil; Feasibility Studi | 2002 |